Retatrutide and Tirzepatide from ₱750 a vial in 25, 50 and 100 packs. Split it with friends or resell it under your own label.From ₱750 a vial: 25, 50 and 100 packs for group buys and resellers.See bulk prices →
Weight loss · Compound
AOD-9604
Synthetic fragment of human growth hormone (hGH 176-191) studied for effects on fat metabolism in animal work and in a phase 2b obesity trial.
Philippines Peptides editorial deskUpdated Trial data checked 23 September 20266 min read5 sources
AOD-9604 is not yet in the evidence datasets this site draws on, so this page makes no claim about what it does.
What is AOD-9604
AOD-9604 is a synthetic peptide fragment derived from the C-terminal end of human growth hormone, amino acids 176 to 191. Researchers isolated this region because, in animal and tissue studies (Ng 2000; Heffernan 2001), it was associated with growth hormone's effects on fat metabolism. Browse the full peptide library for related compounds.
Phosphagenics Limited ran a phase 2b randomised, placebo-controlled trial of AOD-9604 in obese adults with a 12-week endpoint (2007). A 2013 paper (Stier et al.) reviewed its safety and tolerability data in humans. AOD-9604 had no Philippine drug registration in the FDA Philippines database when checked on 7 May 2026.
GLP-1 peptides act on hormone receptors involved in appetite. The AOD-9604 studies cited on this page examined fat breakdown (lipolysis) and fat storage (lipogenesis) in animal and tissue models instead. Tesamorelin, a growth hormone-releasing hormone analogue, is covered on its own page.
How it works
Lipolysis: in animal and tissue studies (Ng 2000; Heffernan 2001), AOD-9604 increased the breakdown of stored fat into free fatty acids. These are animal and tissue findings.
Lipogenesis: the same animal and tissue studies examined the conversion of nutrients into stored fat, which the fragment reduced.
Beta-3 adrenergic receptors: a 2001 mouse study (Heffernan et al.) compared obese mice with mice lacking the beta-3 adrenergic receptor to examine whether the fragment's effects on fat metabolism depend on that receptor.
On the ground in the Philippines
AOD-9604 had no Philippine drug registration in the FDA Philippines registered drug products database when it was checked on 7 May 2026.
Benefits studied
AOD-9604 is not yet in the evidence datasets this site draws on, so this page makes no claim about what it does. Anything published about it elsewhere should be read with its evidence level in mind: most peptides in this category have animal or cell data only.
Side effects reported
No controlled human data on adverse events for AOD-9604 is in the datasets this site draws on, so its safety in people is unknown rather than established. Effects commonly described for it are listed below; how often they occur has not been measured in a controlled trial.
Injection site redness or swelling
Flushing or warmth after injection
Fatigue
Headache
Dizziness after injection
Nausea
Regulatory status
The regulatory dataset this site draws on has no row for AOD-9604.
Who should not use AOD-9604
Everything above is research framing. If you have got as far as wanting a vial, the catalogue at Primara Labs, our partner and supplier, is the shortest way to see what is held inside the Philippines and at what price. View the Primara Labs catalogue
FAQ
What evidence exists for AOD-9604?
The sources cited on this page are animal and tissue studies of fat metabolism (Ng 2000; Heffernan 2001), a phase 2b randomised, placebo-controlled trial in obese adults with a 12-week endpoint (2007), and a 2013 paper on safety and tolerability in humans (Stier et al.). AOD-9604 is not in the evidence datasets this site draws on, so no benefit or trial figure is shown on this page.
How does AOD-9604 differ from GLP-1 peptides?
GLP-1 peptides such as retatrutide and tirzepatide act on hormone receptors involved in appetite and blood sugar. The AOD-9604 studies cited on this page examined fat breakdown and fat storage in animal and tissue models. No trial comparing AOD-9604 with a GLP-1 peptide is cited here.
Is AOD-9604 registered in the Philippines?
The regulatory dataset this site draws on has no row for AOD-9604. A check of the FDA Philippines registered drug products database on 7 May 2026, cited in this page's sources, found no Philippine drug registration for it. See the regulatory status page.
Where to get AOD-9604 in the Philippines
Primara Labs, our partner and supplier, lists their current vials on the catalogue. Prices and stock change, so check there for what is available now. View the Primara Labs catalogue
The supply index covers what to ask a seller before paying, and why quoted prices vary so widely.
Citations supporting the clinical claims on this page. Each entry links to the primary record.
All 5 sources: AOD-9604 mechanism: Heffernan 2001, Lipolytic domain metabolic studies: Ng 2000, Phase 2b obesity trial: AOD-9604 and more
1.
AOD-9604 mechanism: Heffernan 2001Mechanism
Heffernan M, Summers RJ, Thorburn A, et al. "The effects of human growth hormone and its lipolytic fragment (AOD9604) on lipid metabolism." Endocrinology 2001;142(12):5182–5189.
FDA Philippines drug registry: AOD-9604 not listedReference
FDA Philippines Registered Drug Products Database. Verified 2026-05-07: AOD-9604 has no Philippine drug registration; available only as research-grade peptide.
This page is editorial information for adults researching peptide therapy. It is not medical advice, not a prescription, and not an endorsement of any specific product, supplier, or protocol. Side effects can be serious and individual response varies. Talk to a licensed physician (ideally one with peptide-specific clinical experience) before starting any compound, adjusting a dose, or discontinuing therapy.
In the Philippines, GLP-1 medications are prescription-only under FDA Philippines regulation. Research-grade peptides occupy a regulatory gray area: import for personal research use is generally tolerated, but the Bureau of Customs reserves the right to inspect and detain shipments. Do not import for resale.
